Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Feb 15

PMID 33585211

Citations 7

Authors

Xiaoqin Ji

Yulu Zhao

Xixu Zhu

Zetian Shen

Aomei Li

Cheng Chen

Xiaoyuan Chu

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the clinical outcomes of metastatic colorectal cancer (mCRC) patients with oligometastases, oligoprogression, or local control of dominant tumors after stereotactic body radiotherapy (SBRT) and establish a nomogram model to predict the prognosis for these patients.

Methods And Materials: A cohort of 94 patients with 162 mCRC metastases was treated with SBRT at a single institution. Treatment indications were oligometastases, oligoprogression, and local control of dominant tumors. End points of this study were the outcome in terms of progression-free survival (PFS), overall survival (OS), local progression (LP), and cumulative incidence of starting or changing systemic therapy (SCST). In addition, univariate and multivariable analyses to assess variable associations were performed. The predictive accuracy and discriminative ability of the nomogram were determined by concordance index (C-index) and calibration curve.

Results: Median PFS were 12.6 months, 6.8 months, and 3.7 months for oligometastases, oligoprogression, and local control of dominant tumors, respectively. 0-1 performance status, < 10 ug/L pre-SBRT CEA, and ≤ 2 metastases were significant predictors of higher PFS on multivariate analysis. Median OS were 40.0 months, 26.1 months, and 6.5 months for oligometastases, oligoprogression, and local control of dominant tumors, respectively. In the multivariate analysis of the cohort, the independent factors for survival were indication, performance status, pre-SBRT CEA, and PTV, all of which were selected into the nomogram. The calibration curve for probability of survival showed the good agreement between prediction by nomogram and actual observation. The C-index of the nomogram for predicting survival was 0.848.

Conclusions: SBRT for metastases derived from colorectal cancer offered favorable survival and symptom palliation without significant complications. The proposed nomogram could provide individual prediction of OS for patients with mCRC after SBRT.

Citing Articles

Predicting extensive metastasis in postoperative oligometastatic colorectal cancer.

Fan R, Mao C, Zhang J, Dai M, Zhang R, Wang X Int J Colorectal Dis. 2025; 40(1):53.

PMID: 40000449 PMC: 11861249. DOI: 10.1007/s00384-025-04841-w.

Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study.

Zagardo V, Martorana E, Harikar M, Pergolizzi S, Ferini G Discov Oncol. 2024; 15(1):531.

PMID: 39377996 PMC: 11461402. DOI: 10.1007/s12672-024-01360-y.

Is red blood cell distribution width a prognostic factor for colorectal cancer? A meta-analysis.

Wen Z, Zhou X, Xiao D Front Surg. 2022; 9:945126.

PMID: 36263092 PMC: 9574073. DOI: 10.3389/fsurg.2022.945126.

Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases.

Lindberg S, Onjukka E, Wersall P, Staff C, Lewensohn R, Masucci G Clin Transl Radiat Oncol. 2022; 36:91-98.

PMID: 35942398 PMC: 9356237. DOI: 10.1016/j.ctro.2022.07.006.

Higher body mass index was associated with better prognosis in diabetic patients with stage II colorectal cancer.

Liu X, Kang B, Cheng Y, Yuan C, Tao W, Zhang B BMC Cancer. 2022; 22(1):596.

PMID: 35641911 PMC: 9158211. DOI: 10.1186/s12885-022-09691-1.

References

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Huitzil-Melendez F, Capanu M, OReilly E, Duffy A, Gansukh B, Saltz L . Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. J Clin Oncol. 2010; 28(17):2889-95. PMC: 3651603. DOI: 10.1200/JCO.2009.25.9895. View

Timmerman R, Herman J, Cho L . Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014; 32(26):2847-54. PMC: 4152712. DOI: 10.1200/JCO.2014.55.4675. View

Straka C, Kim D, Timmerman R, Pedrosa I, Jacobs C, Brugarolas J . Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol. 2013; 31(23):e401-3. PMC: 4878052. DOI: 10.1200/JCO.2012.47.7455. View

Helou J, Thibault I, Poon I, Chiang A, Jain S, Soliman H . Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter. Int J Radiat Oncol Biol Phys. 2017; 98(2):419-427. DOI: 10.1016/j.ijrobp.2017.02.093. View

Fode M, Hoyer M . Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015; 114(2):155-60. DOI: 10.1016/j.radonc.2014.12.003. View

Patanaphan V, Salazar O . Colorectal cancer: metastatic patterns and prognosis. South Med J. 1993; 86(1):38-41. View

Kang J, Kim M, Kim J, Yoo S, Cho C, Yang K . Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010; 27(4):273-8. DOI: 10.1007/s10585-010-9325-0. View

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D . Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii1-9. DOI: 10.1093/annonc/mdu260. View

10.

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A . Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017; 116(12):1520-1525. PMC: 5518848. DOI: 10.1038/bjc.2017.103. View

11.

Tree A, Khoo V, Eeles R, Ahmed M, Dearnaley D, Hawkins M . Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14(1):e28-37. DOI: 10.1016/S1470-2045(12)70510-7. View

12.

Renfro L, Goldberg R, Grothey A, Sobrero A, Adams R, Seymour M . Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2017; 35(17):1929-1937. PMC: 5466009. DOI: 10.1200/JCO.2016.71.5771. View

13.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

14.

Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A . Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2016; 28(3):555-561. DOI: 10.1093/annonc/mdw627. View

15.

Sjoquist K, Renfro L, Simes R, Tebbutt N, Clarke S, Seymour M . Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2017; 110(6):638-648. PMC: 6005015. DOI: 10.1093/jnci/djx253. View

16.

Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N . Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol. 2020; 196(9):813-820. DOI: 10.1007/s00066-020-01627-7. View

17.

Timmerman R . An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008; 18(4):215-22. DOI: 10.1016/j.semradonc.2008.04.001. View

18.

Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F . Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2018; 133:220-226. DOI: 10.1016/j.radonc.2018.10.024. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

20.

Helou J, Thibault I, Chu W, Munoz-Schuffenegger P, Erler D, Rodrigues G . Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis. Radiother Oncol. 2018; 129(3):435-440. DOI: 10.1016/j.radonc.2018.09.011. View